# A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis

> **NCT01142583** · — · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 192 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01142583
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2014-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01142583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01142583, "A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01142583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*